Comparación de la precisión diagnóstica de la tomografía computarizada de haz cónico y tres sistemas radiográficos intraorales en la detección de lesiones de caries in vitro.

Objective: The objective of the study was to compare the diagnostic accuracy of cone beam computed tomography and three intraoral radiographic systems in the detection of in vitro caries lesions. Material and Methods: One hundred teeth (46 molars and 54 premolars) were evaluated, including 176 proximal surfaces and 90 occlusal surfaces, with or without dental caries lesions. Digital images of all teeth were obtained using specific intraoral radiographs, VistaScan DürrDental®phosphor-plate radiography, XIOS XG Sirona® digital sensor radiography, and CBCT I-CATTM. Observers evaluated the images for the detection of caries lesions. The teeth were clinically sectioned and stereomicroscopy served as a validation tool. The relationship of sensitivity and specificity between all systems was determined through the ROC curve using Az values. Results: The values of the area under the curve (Az) selected for the CBCT I-CATTM system were 0.89 (0.84-0.93), for conventional radiography 0.71 (0.66-0.76), digital sensor radiography 0.74 (0.70-0.78) and digital radiography with phosphor-plates 0.73 (0.69-0.77). Statistically significant differences were found between the CBCT I-CATTM system and intraoral radiographic systems (p<0.01). The sensitivity and specificity values for the CBCT I-CATTM were 0.84 and 0.93 respectively. Conclusion: CBCT has a high sensitivity and specificity compared to intraoral radiographic systems for the diagnosis of dental caries lesions in vitro.Objetivo: El objetivo del estudio fue comparar la precisión diagnóstica de la tomografía computarizada de haz cónico y tres sistemas radiográficos intraorales en la detección de lesiones de caries in vitro. Material y Métodos: Se evaluaron 100 dientes, 46 molares y 54 premolares; 176 superficies proximales y 90 superficies oclusales, con o sin lesión de caries dental. Se obtuvieron imágenes digitales de todos los dientes utilizando radiografías intraorales convencionales, radiografía con placas de fósforo VistaScan Du?rrDental®, radiografía con sensor digital XIOS XG Sirona® y CBCT I-CATTM. Tres observadores evaluaron las imágenes para la detección de lesiones de caries. Los dientes se seccionaron clínicamente y la estereomicroscopía sirvió como herramienta de validación. Se determinó relación de sensibilidad y especificidad entre todos los sistemas a través de la curva ROC utilizando valores Az. Resultados: Los valores de área debajo de la curva (Az) obtenidos para el sistema CBCT I-CATTM fueron de 0.89 (0.84-0.93), para radiografía convencional 0.71 (0.66-0.76), radiografía con sensor digital 0.74 (0.70-0.78) y radiografía digital con placas de fósforo 0.73 (0.69-0.77). Se encontró diferencias estadísticamente significativas entre el sistema CBCT I-CATTM y todos los sistemas radiográficos convencionales y digitales (p<0.01). Los valores de sensibilidad y especificidad para el CBCT I-CATTM fueron 0.84 y 0.93 respectivamente. Conclusión: La CBCT tiene una alta sensibilidad y especificidad en comparación a los sistemas radiográficos intraorales en el diagnóstico de lesiones de caries dental in vitro

User Centered Design to Improve Information Exchange in Diabetes Care Through eHealth: Results from a Small Scale Exploratory Study

[EN] Heterogeneity of people with diabetes makes maintaining blood glucose control and achieving therapy adherence a challenge. It is fundamental that patients get actively involved in the management of the disease in their living environments. The objective of this paper is to evaluate the use and acceptance of a self-management system for diabetes developed with User Centered Design Principles in community settings. Persons with diabetes and health professionals were involved the design, development and evaluation of the self-management system; which comprised three iterative cycles: scenario definition, user archetype definition and system development. A comprehensive system was developed integrating modules for the management of blood glucose levels, medication, food intake habits, physical activity, diabetes education and messaging. The system was adapted for two types of principal users (personas): Type 1 Diabetes user and Type 2 Diabetes user. The system was evaluated by assessing the use, the compliance, the attractiveness and perceived usefulness in a multicenter randomized pilot study involving 20 patients and 24 treating professionals for a period of four weeks. Usage and compliance of the co-designed system was compared during the first and the last two weeks of the study, showing a significantly improved behaviour of patients towards the system for each of the modules. This resulted in a successful adoption by both type of personas. Only the medication module showed a significantly different use and compliance (p= 0.01) which can be explained by the different therapeutic course of the two types of diabetes. The involvement of patients to make their own decisions and choices form design stages was key for the adoption of a self-management system for diabetes.This study was funded by European Commission under the 7th Framework Program grant agreement number 216270.3.Fico, G.; Martinez-Millana, A.; Leuteritz, J.; Fioravanti, A.; Beltrán-Jaunsarás, ME.; Traver Salcedo, V.; Arredondo, MT. (2019). User Centered Design to Improve Information Exchange in Diabetes Care Through eHealth: Results from a Small Scale Exploratory Study. Journal of Medical Systems. 44(1):1-12. https://doi.org/10.1007/s10916-019-1472-5S112441Nolte, E, and McKee, M, Caring for People with Chronic Conditions: A Health System Perspective. UK: McGraw-Hill Education, 2008. ISBN 9780335236909.Bodenheimer, T, Lorig, K, Holman, H, and Grumbach K, PAtient self-management of chronic disease in primary care. JAMA 288(19):2469–2475, 2002. https://doi.org/10.1001/jama.288.19.2469. ISSN 0098-7484.American Diabetes Association, Standards of Medical Care in Diabetes—2008. Diabetes Care 31(Supplement 1): S12–S54, 2008. https://doi.org/10.2337/dc08-S012, http://care.diabetesjournals.org/content/31/Supplement_1/S12.Inzucchi, S E, Bergenstal, R M, Buse, J B, Diamant, M, Ferrannini, E, Nauck, M, Peters, A L, Tsapas, A, Wender, R, and Matthews, D R, Management of hyperglycemia in type 2 Diabetes, 2015: a patient-centered approach: update to a position statement of the American diabetes association and the European association for the study of diabetes. Diabetes Care 38(1):140–149, 2015. https://doi.org/10.2337/dc14-2441. ISSN 19355548.Zarkogianni, K, Litsa, E, Mitsis, K, Wu, P, Kaddi, C, Cheng, C, Wang, M, and Nikita, K, A review of emerging technologies for the management of diabetes mellitus. IEEE Trans. Bio-Med. Eng. PP(99):1, 2015. https://doi.org/10.1109/TBME.2015.2470521. http://www.ncbi.nlm.nih.gov/pubmed/26292334.Reutens, A T, Hutchinson, R, Binh, T V, Cockram, C, Deerochanawong, C, Ho, L T, Ji, L, Khalid, B A K, Kong, A P S, Lim-Abrahan, M A, Tan, C E, Tjokroprawiro, A, Yoon, K H, Zmmet, P Z, and Shaw, J E, The GIANT study, a cluster-randomised controlled trial of efficacy of education of doctors about type 2 diabetes mellitus management guidelines in primary care practice. Diabetes Res. Clin. Pract. 98(1): 38–45, 2012. https://doi.org/10.1016/j.diabres.2012.06.002. ISSN 01688227.Aslan, S., Ciocca, G., and Schettini, R.: Semantic segmentation of food images for automatic dietary monitoring. In: 2018 26th Signal Processing and Communications Applications Conference (SIU), pp. 1–4, 2018, https://doi.org/10.1109/SIU.2018.8404824.Gómez, E J, Hernando Pérez, M E, Vering, T, Cros, M R, Bott, O, García-Sáez, G, Pretschner, P, Bruguéz, E, Schnell, O, Patte, C, Bergmann, J, Dudde, R, and de Leiva, A, The INCA system: A further step towards a telemedical artificial pancreas. IEEE Trans. Inf. Technol. Biomed. 12(4): 470–479, 2008. https://doi.org/10.1109/TITB.2007.902162. ISSN 10897771.Martinez-Millana, A, Fico, G, Fernández-Llatas, C, and Traver, V, Performance assessment of a closed-loop system for diabetes management. Med. Biol. Eng. Comput. 53(12):1295–1303, 2015. https://doi.org/10.1007/s11517-015-1245-3. ISSN 1741-0444.Oreskovic, N M, Maniates, J, Weilburg, J, and Choy, G, Optimizing the use of electronic health records to identify high-risk psychosocial determinants of Health. JMIR Med. Inf. 5 (3): e25, 2017. https://doi.org/10.2196/medinform.8240. http://medinform.jmir.org/2017/3/e25/.Conte, R., Sansone, F., Grande, A., Tonacci, A., Napoli, F., Pala, A. P., Raciti, M., and Landi, P.: Development of an integrated ict system for data production, standardization and elaboration in health care. In: 2017 E-Health and Bioengineering Conference (EHB). https://doi.org/10.1109/EHB.2017.7995426, pp. 321–324, 2017.Ryu, B, Kim, N, Heo, E, Yoo, S, Lee, K, Hwang, H, Kim, J.-W., Kim, Y, Lee, J, and Jung, S Y, Impact of an electronic health record-integrated personal health record on patient participation in health care: development and randomized controlled trial of MyHealthKeeper. J. Med. Int. Res. 19(12):e401, 2017. https://doi.org/10.2196/jmir.8867. http://www.jmir.org/2017/12/e401/.Chavez, S, Fedele, D, Guo, Y, Bernier, A, Smith, M, Warnick, J, and Modave, F, Mobile Apps for the management of diabetes. Diabetes Care 40(10):e145–e146, 2017. https://doi.org/10.2337/dc17-0853. http://care.diabetesjournals.org/lookup/doi/10.2337/dc17-0853.Irace, C, Schweitzer, M A, Tripolino, C, Scavelli, F B, and Gnasso, A, Diabetes data management system to improve glycemic control in people with type 1 Diabetes: Prospective cohort study. JMIR mHealth uHealth 5(11):e170, 2017. https://doi.org/10.2196/mhealth.8532. http://mhealth.jmir.org/2017/11/e170/.Helal, A, Cook, D J, and Schmalz, M, Smart home-based health platform for behavioral monitoring and alteration of diabetes patients. J. Diabetes Sci. Technol. 3(1):141–148, 2009. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2769843/.Synnott, J, Chen, L, Nugent, C D, and Moore, G: Flexible and customizable visualization of data generated within intelligent environments. In: 2012 Annual International Conference of the IEEE Engineering in Medicine and Biology Society. https://doi.org/10.1109/EMBC.2012.6347317, pp. 5819–5822, 2012.Shahar, Y, Goren-Bar, D, Boaz, D, and Tahan, G, Distributed, intelligent, interactive visualization and exploration of time-oriented clinical data and their abstractions. Artif. Intell. Med. 38(2):115–135, 2006. https://doi.org/10.1016/j.artmed.2005.03.001.Fico, G., Fioravanti, A., Teresa Arredondo, M., Gorman, J., Diazzi, C., Arcuri, G., Conti, C., and Pirini, G., Integration of personalized healthcare pathways in an ict platform for diabetes managements: a small-scale exploratory study. IEEE J. Biomed. Health Inf. 20(1):29–38, 2016. https://doi.org/10.1109/JBHI.2014.2367863. ISSN 2168-2194.Salzburg Global Seminar, Salzburg statement on shared decision making. BMJ 342:d1745, 2011. https://doi.org/10.1136/bmj.d1745, http://www.bmj.com/content/342/bmj.d1745.Stacey, D, Bennett, C L, Barry, M J, Col, N F, Eden, K B, Holmes-Rovner, M, Llewellyn-Thomas, H, Lyddiatt, A, Légaré, F, and Thomson, R, Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst. Rev. 10:CD001431, 2011. https://doi.org/10.1002/14651858.CD001431.pub3. ISSN 1469-493X.Gabert, R, Thomson, B, Gakidou, E, and Roth, G, Identifying high-risk neighborhoods using electronic medical records: a population-based approach for targeting diabetes prevention and treatment interventions. PloS one 11(7):e0159227, 2016. https://doi.org/10.1371/journal.pone.0159227. ISSN 19326203.Barry, M J, and Edgman-Levitan S, Shared decision making — the pinnacle of patient-centered care. England J. Med. 366(9):780–781, 2012. https://doi.org/10.1056/NEJMp1109283. ISSN 0028-4793.Fico, G, Cancela, J, Arredondo, M T, Dagliati, A, Sacchi, L, Segagni, D, Millana, A M, Fernandez-Llatas, C, Traver, V, Sambo, F, et al: User requirements for incorporating diabetes modeling techniques in disease management tools. In: 6th European Conference of the International Federation for Medical and Biological Engineering, pp. 992–995. Springer, 2015.Draznin, B, Gilden, J, Golden, S H, and Inzucchi, S E, Pathways to quality inpatient management of hyperglycemia and diabetes: A call to action. Diabetes Care 36(7):1807–1814, 2013. https://doi.org/10.2337/dc12-2508. ISSN 01495992.Nielsen, J, and Molich, R: Heuristic evaluation of user interfaces. In: Proceedings of the SIGCHI Conference on Human Factors in Computing Systems, CHI ’90, pp. 249–256. ACM, New York, 1990.. http://doi.acm.org/10.1145/97243.97281Flores, A E, Ph, D, and Vergara, V M: Functionalities of open electronic health records system. Biomed. Eng. (Bmei), 602–607. http://ieeexplore.ieee.org/xpls/abs_all.jsp?arnumber=6747011, 2013Guillén, A, Colás, J, Fico, G, and Guillén, S: Metabo: a new paradigm towards diabetes disease management. An innovative business model. In: 2011 Annual International Conference of the IEEE Engineering in Medicine and Biology Society, EMBC, pp. 3554–3557. IEEE, 2011.Hassenzahl, M, Burmester, M, and Koller, F: Attrakdiff: Ein fragebogen zur messung wahrgenommener hedonischer und pragmatischer qualität. In: Mensch & Computer 2003, pp. 187–196. Springer, 2003.Davis, F D: Perceived usefulness, perceived ease of use, and user acceptance of information technology. MIS Quart., 319–340, 1989Fioravanti, A, Fico, G, Salvi, D, García-Betances, R I, and Arredondo, M T, Automatic messaging for improving patient’s engagement in diabetes management: an exploratory study. Med. Biol. Eng. Comput. 53(12): 1285–1294, 2015. https://doi.org/10.1007/s11517-014-1237-8. ISSN 0140-0118.Haas, L, Maryniuk, M, Beck, J, Cox, C E, Duker, P, Edwards, L, Fisher, E B, Hanson, L, Kent, D, Kolb, L, McLaughlin, S, Orzeck, E, Piette, J D, Rhinehart, A S, Rothman, R, Sklaroff, S, Tomky, D, and Youssef, G., National standards for diabetes self-management education and support. Diabetes Care 35(11):2393–2401, 2012. https://doi.org/10.2337/dc12-1707. ISSN 01495992.Quinn, C C, Sareh, P L, Shardell, M L, Terrin, M L, Barr, E A, and Gruber-Baldini, A L, Mobile diabetes intervention for glycemic control. J. Diabetes Sci. Technol. 8(2):362–370, 2014. http://journals.sagepub.com/doi/10.1177/1932296813514503

El efecto de los temporales de viento en la laurisilva de anaga (Tenerife. I. Canarias). La tormenta delta de noviembre de 2005

La accidentada topografía del Macizo de Anaga y la localización de la laurisilva en los relieves más expuestos contribuyen a que los daños forestales inmediatos de los temporales sean notorios. La relación de este efecto con la magnitud del vendaval está cada vez más condicionada por el aumento de la madurez del bosque debido al abandono de los aprovechamientos forestales. 18 meses después de la tormenta Delta el bosque evidencia un proceso de autosucesión y el fin del enriquecimiento del sotobosque con especies herbáceas heliófilas. Esta dinámica indica que a medio y largo plazo las consecuencias serán exclusivamente fisonómicas. Tras comprobar la recurrencia histórica de estos fenómenos atmosféricos, el objetivo final de la investigación iniciada con este trabajo es valorar la importancia de los temporales de viento en la dinámica del paisaje forestal de Anaga

Abstracts

Tradução dos Resumos, para a língua inglesa, dos artigos publicados nesta edição

In the eye of the student : "An intangible cultural heritage experience, with a human-computer interaction twist"

We critically engage with CHI communities emerging outside the global North (ArabHCI and AfriCHI) to explore how participation is configured and enacted within sociocultural and political contexts fundamentally different from Western societies. We contribute to recent discussions about postcolonialism and decolonization of HCI by focusing on non-Western future technology designers. Our lens was a course designed to engage Egyptian students with a local yet culturally-distant community to design applications for documenting intangible heritage. Through an action research, the instructors reflect on selected students' activities. Despite deploying a flexible learning curriculum that encourages greater autonomy, the students perceived themselves with less agency than other institutional stakeholders involved in the project. Further, some of them struggled to empathize with the community as the impact of the cultural differences on configuring participation was profound. We discuss the implications of the findings on HCI education and in international cross-cultural design projects

Understanding the potential impact of different drug properties on SARS-CoV-2 transmission and disease burden : a modelling analysis

Q1Q1Background The unprecedented public health impact of the COVID-19 pandemic has motivated a rapid search for potential therapeutics, with some key successes. However, the potential impact of different treatments, and consequently research and procurement priorities, have not been clear. Methods and Findings develop a mathematical model of SARS-CoV-2 transmission, COVID-19 disease and clinical care to explore the potential public-health impact of a range of different potential therapeutics, under a range of different scenarios varying: i) healthcare capacity, ii) epidemic trajectories; and iii) drug efficacy in the absence of supportive care. In each case, the outcome of interest was the number of COVID-19 deaths averted in scenarios with the therapeutic compared to scenarios without. We find the impact of drugs like dexamethasone (which are delivered to the most critically-ill in hospital and whose therapeutic benefit is expected to depend on the availability of supportive care such as oxygen and mechanical ventilation) is likely to be limited in settings where healthcare capacity is lowest or where uncontrolled epidemics result in hospitals being overwhelmed. As such, it may avert 22% of deaths in highincome countries but only 8% in low-income countries (assuming R=1.35). Therapeutics for different patient populations (those not in hospital, early in the course of infection) and types of benefit (reducing disease severity or infectiousness, preventing hospitalisation) could have much greater benefits, particularly in resource-poor settings facing large epidemics. Conclusions There is a global asymmetry in who is likely to benefit from advances in the treatment of COVID-19 to date, which have been focussed on hospitalised-patients and predicated on an assumption of adequate access to supportive care. Therapeutics that can feasibly be delivered to those earlier in the course of infection that reduce the need for healthcare or reduce infectiousness could have significant impact, and research into their efficacy and means of delivery should be a priorityRevista Internacional - Indexad

Un examen actualizado de la percepción de las barreras para la implementación de la farmacogenómica y la utilidad de los pares fármaco/gen en América Latina y el Caribe

La farmacogenómica (PGx) se considera un campo emergente en los países en desarrollo. La investigación sobre PGx en la región de América Latina y el Caribe (ALC) sigue siendo escasa, con información limitada en algunas poblaciones. Por lo tanto, las extrapolaciones son complicadas, especialmente en poblaciones mixtas. En este trabajo, revisamos y analizamos el conocimiento farmacogenómico entre la comunidad científica y clínica de ALC y examinamos las barreras para la aplicación clínica. Realizamos una búsqueda de publicaciones y ensayos clínicos en este campo en todo el mundo y evaluamos la contribución de ALC. A continuación, realizamos una encuesta regional estructurada que evaluó una lista de 14 barreras potenciales para la aplicación clínica de biomarcadores en función de su importancia. Además, se analizó una lista emparejada de 54 genes/fármacos para determinar una asociación entre los biomarcadores y la respuesta a la medicina genómica. Esta encuesta se comparó con una encuesta anterior realizada en 2014 para evaluar el progreso en la región. Los resultados de la búsqueda indicaron que los países de América Latina y el Caribe han contribuido con el 3,44% del total de publicaciones y el 2,45% de los ensayos clínicos relacionados con PGx en todo el mundo hasta el momento. Un total de 106 profesionales de 17 países respondieron a la encuesta. Se identificaron seis grandes grupos de obstáculos. A pesar de los continuos esfuerzos de la región en la última década, la principal barrera para la implementación de PGx en ALC sigue siendo la misma, la "necesidad de directrices, procesos y protocolos para la aplicación clínica de la farmacogenética/farmacogenómica". Las cuestiones de coste-eficacia se consideran factores críticos en la región. Los puntos relacionados con la reticencia de los clínicos son actualmente menos relevantes. Según los resultados de la encuesta, los pares gen/fármaco mejor clasificados (96%-99%) y percibidos como importantes fueron CYP2D6/tamoxifeno, CYP3A5/tacrolimus, CYP2D6/opioides, DPYD/fluoropirimidinas, TMPT/tiopurinas, CYP2D6/antidepresivos tricíclicos, CYP2C19/antidepresivos tricíclicos, NUDT15/tiopurinas, CYP2B6/efavirenz y CYP2C19/clopidogrel. En conclusión, aunque la contribución global de los países de ALC sigue siendo baja en el campo del PGx, se ha observado una mejora relevante en la región. La percepción de la utilidad de las pruebas PGx en la comunidad biomédica ha cambiado drásticamente, aumentando la concienciación entre los médicos, lo que sugiere un futuro prometedor en las aplicaciones clínicas de PGx en ALC.Pharmacogenomics (PGx) is considered an emergent field in developing countries. Research on PGx in the Latin American and the Caribbean (LAC) region remains scarce, with limited information in some populations. Thus, extrapolations are complicated, especially in mixed populations. In this paper, we reviewed and analyzed pharmacogenomic knowledge among the LAC scientific and clinical community and examined barriers to clinical application. We performed a search for publications and clinical trials in the field worldwide and evaluated the contribution of LAC. Next, we conducted a regional structured survey that evaluated a list of 14 potential barriers to the clinical implementation of biomarkers based on their importance. In addition, a paired list of 54 genes/drugs was analyzed to determine an association between biomarkers and response to genomic medicine. This survey was compared to a previous survey performed in 2014 to assess progress in the region. The search results indicated that Latin American and Caribbean countries have contributed 3.44% of the total publications and 2.45% of the PGx-related clinical trials worldwide thus far. A total of 106 professionals from 17 countries answered the survey. Six major groups of barriers were identified. Despite the region’s continuous efforts in the last decade, the primary barrier to PGx implementation in LAC remains the same, the “need for guidelines, processes, and protocols for the clinical application of pharmacogenetics/pharmacogenomics”. Cost-effectiveness issues are considered critical factors in the region. Items related to the reluctance of clinicians are currently less relevant. Based on the survey results, the highest ranked (96%–99%) gene/drug pairs perceived as important were CYP2D6/tamoxifen, CYP3A5/tacrolimus, CYP2D6/opioids, DPYD/fluoropyrimidines, TMPT/thiopurines, CYP2D6/tricyclic antidepressants, CYP2C19/tricyclic antidepressants, NUDT15/thiopurines, CYP2B6/efavirenz, and CYP2C19/clopidogrel. In conclusion, although the global contribution of LAC countries remains low in the PGx field, a relevant improvement has been observed in the region. The perception of the usefulness of PGx tests in biomedical community has drastically changed, raising awareness among physicians, which suggests a promising future in the clinical applications of PGx in LAC

An Updated Examination of the Perception of Barriers for Pharmacogenomics Implementation and the Usefulness of Drug/Gene Pairs in Latin America and the Caribbean

Pharmacogenomics (PGx) is considered an emergent field in developing countries. Research on PGx in the Latin American and the Caribbean (LAC) region remains scarce, with limited information in some populations. Thus, extrapolations are complicated, especially in mixed populations. In this paper, we reviewed and analyzed pharmacogenomic knowledge among the LAC scientific and clinical community and examined barriers to clinical application. We performed a search for publications and clinical trials in the field worldwide and evaluated the contribution of LAC. Next, we conducted a regional structured survey that evaluated a list of 14 potential barriers to the clinical implementation of biomarkers based on their importance. In addition, a paired list of 54 genes/drugs was analyzed to determine an association between biomarkers and response to genomic medicine. This survey was compared to a previous survey performed in 2014 to assess progress in the region. The search results indicated that Latin American and Caribbean countries have contributed 3.44% of the total publications and 2.45% of the PGx-related clinical trials worldwide thus far. A total of 106 professionals from 17 countries answered the survey. Six major groups of barriers were identified. Despite the region’s continuous efforts in the last decade, the primary barrier to PGx implementation in LAC remains the same, the “need for guidelines, processes, and protocols for the clinical application of pharmacogenetics/pharmacogenomics”. Cost-effectiveness issues are considered critical factors in the region. Items related to the reluctance of clinicians are currently less relevant. Based on the survey results, the highest ranked (96%–99%) gene/drug pairs perceived as important were CYP2D6/tamoxifen, CYP3A5/tacrolimus, CYP2D6/opioids, DPYD/fluoropyrimidines, TMPT/thiopurines, CYP2D6/tricyclic antidepressants, CYP2C19/tricyclic antidepressants, NUDT15/thiopurines, CYP2B6/efavirenz, and CYP2C19/clopidogrel. In conclusion, although the global contribution of LAC countries remains low in the PGx field, a relevant improvement has been observed in the region. The perception of the usefulness of PGx tests in biomedical community has drastically changed, raising awareness among physicians, which suggests a promising future in the clinical applications of PGx in LAC

Ahora / Ara

La cinquena edició del microrelatari per l’eradicació de la violència contra les dones de l’Institut Universitari d’Estudis Feministes i de Gènere «Purificación Escribano» de la Universitat Jaume I vol ser una declaració d’esperança. Aquest és el moment en el qual les dones (i els homes) hem de fer un pas endavant i eliminar la violència sistèmica contra les dones. Ara és el moment de denunciar el masclisme i els micromasclismes començant a construir una societat més igualitària. Cadascun dels relats del llibre és una denúncia i una declaració que ens encamina cap a un món millor

Sin / Sense

Sexto desafío por la erradicación de la violencia contra las mujeres del Institut Universitari d’Estudis Feministes i de Gènere «Purificación Escribano» de la Universitat Jaume